David Hung

David Hung

Fondateur chez NUVATION BIO INC.

Fortune : 289 M $ au 31/05/2026

68 ans
Health Technology
Finance
Consumer Services

Profil

David T.
Hung
was the founder of Medivation LLC (California), founded in 1995, where the titles held included President, Chief Executive Officer & Director from 2003 to 2016.
Dr. Hung was the founder of Medivation, Inc., founded in 2003, with titles of President, Chief Executive Officer & Director from 2003 to 2016.
Dr. Hung is the founder of Nuvation Bio Operating Co., Inc., founded in 2018, holding the titles of President, Chief Executive Officer & Director since 2018.
Dr. Hung is the founder of Nuvation Bio, Inc., founded in 2018, holding the titles of President, Chief Executive Officer & Director since 2018.
Dr. Hung is also the founder of Repharmation, Inc...
Dr. Hung currently serves as Chairman at T-Therapeutics Ltd. Dr. Hung is an Independent Director at NovoCure Ltd. since 2018.
Dr. Hung is a Director at Establishment Labs SA since 2016.
Dr. Hung is a Director at Auransa, Inc. Former positions include President & Chief Executive Officer at Orion Acquisition Corp.
II; President, Chief Executive Officer & Director at Pro-Duct Health, Inc. from 1999 to 2001; President, Chief Executive Officer & Director at Medivation Neurology LLC from 2011 to 2016; Chief Executive Officer & Director at Sio Gene Therapies, Inc. from 2017 to 2018; Chief Executive Officer & Director at Axovant Sciences, Inc. from 2017 to 2018; Director at Agilvax, Inc.; Director at Solbec Pharmaceuticals Ltd.; Independent Director at Opexa Therapeutics, Inc. from 2010 to 2011; Director at NKT Therapeutics, Inc.; Director at Roivant Sciences GmbH; Independent Director at Establishment Labs Holdings, Inc. from 2016 to 2021; Independent Director at ARYA Sciences Acquisition Corp.
from 2018 to 2021; VP-Lead Discovery, Development & New Projects at Chiron Corp.
from 1996 to 1998; Consultant at Cytyc Health Corp.
in 2003.
Education includes undergraduate studies at Harvard College and a doctorate from UCSF School of Medicine.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
25/03/2026 59 281 054 ( 17,02 % ) 283 M $ 31/05/2026
25/03/2026 1 000 000 ( 6,37 % ) 5 M $ 31/05/2026
03/06/2026 32 075 ( 0,03 % ) 546 558 $ 31/05/2026

Postes actifs de David Hung

SociétésPosteDébut
NOVOCURE LIMITED Directeur/Membre du Conseil 31/05/2018
NUVATION BIO INC. Fondateur 20/03/2018
Fondateur 01/01/2018
Directeur/Membre du Conseil -
Repharmation, Inc.
Fondateur -
Directeur/Membre du Conseil 01/02/2016

Anciens postes connus de David Hung

SociétésPosteFin
ESTABLISHMENT LABS HOLDINGS INC. Directeur/Membre du Conseil 11/02/2021
ARYA SCIENCES ACQUISITION CORP. Directeur/Membre du Conseil 01/01/2021
SIO GENE THERAPIES INC. Directeur Général 12/02/2018
░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de David Hung

Formation de David Hung

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

52

Relations au 1er degré

24

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées24

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Cytyc Health Corp.

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Repharmation, Inc.

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. David Hung
-40% : Prolongation exceptionnelle ➤➤➤➤
j
:
:
PROFITEZ-EN MAINTENANT
🔇